Report cover image

Multiple Myeloma Drug Market by Drug (Histone Deacetylase Inhibitors, Immunomodulating Agents, Monoclonal Antibodies), Distribution (Hospital Pharmacy, Online Channel, Retail Pharmacy) - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 15, 2024
Length 184 Pages
SKU # IRE18446304

Description

Multiple Myeloma Drug Market by Drug (Histone Deacetylase Inhibitors, Immunomodulating Agents, Monoclonal Antibodies), Distribution (Hospital Pharmacy, Online Channel, Retail Pharmacy) - Global Forecast 2024-2030


The Multiple Myeloma Drug Market size was estimated at USD 22.70 billion in 2023 and expected to reach USD 24.51 billion in 2024, at a CAGR 8.04% to reach USD 39.02 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Multiple Myeloma Drug Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Multiple Myeloma Drug Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Multiple Myeloma Drug Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Accurex Health Care Manufacturing Inc., Amgen Inc., Bayer AG, Bristol Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche AG, Intas Pharmaceuticals Limited, Johnson & Johnson Services, Inc., Nichi-Iko Pharmaceutical Co., Ltd., Novartis AG, Ono Pharmaceutical Co., Ltd., Pfizer Inc., Sandoz International GmbH, and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Multiple Myeloma Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug

Histone Deacetylase Inhibitors

Immunomodulating Agents

Monoclonal Antibodies

Proteasome Inhibitors
Distribution

Hospital Pharmacy

Online Channel

Retail Pharmacy
Region

Americas
Argentina
Brazil
Canada
Mexico
United States

California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas

Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam

Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Multiple Myeloma Drug Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Multiple Myeloma Drug Market?
3. What are the technology trends and regulatory frameworks in the Multiple Myeloma Drug Market?
4. What is the market share of the leading vendors in the Multiple Myeloma Drug Market?
5. Which modes and strategic moves are suitable for entering the Multiple Myeloma Drug Market?

Note: PDF & Excel + Online Access - 1 Year

Table of Contents

184 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Multiple Myeloma Drug Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increased indication and prevalence of Multiple Myeloma
5.1.1.2. Attractive reimbursement policies supporting treatments in developed countries
5.1.1.3. Increased drug availability along with approvals for generics
5.1.2. Restraints
5.1.2.1. Stringent drug approval process
5.1.3. Opportunities
5.1.3.1. Collaborating product development and drug trials and commercialization
5.1.3.2. Targeted therapy and adoption of Corticosteroids
5.1.4. Challenges
5.1.4.1. Potential side effects
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Multiple Myeloma Drug Market, by Drug
6.1. Introduction
6.2. Histone Deacetylase Inhibitors
6.3. Immunomodulating Agents
6.4. Monoclonal Antibodies
6.5. Proteasome Inhibitors
7. Multiple Myeloma Drug Market, by Distribution
7.1. Introduction
7.2. Hospital Pharmacy
7.3. Online Channel
7.4. Retail Pharmacy
8. Americas Multiple Myeloma Drug Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Multiple Myeloma Drug Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Multiple Myeloma Drug Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player
12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. AbbVie Inc.
12.1.2. Accurex Health Care Manufacturing Inc.
12.1.3. Amgen Inc.
12.1.4. Bayer AG
12.1.5. Bristol Myers Squibb Company
12.1.6. Celgene Corporation
12.1.7. F. Hoffmann-La Roche AG
12.1.8. Intas Pharmaceuticals Limited
12.1.9. Johnson & Johnson Services, Inc.
12.1.10. Nichi-Iko Pharmaceutical Co., Ltd.
12.1.11. Novartis AG
12.1.12. Ono Pharmaceutical Co., Ltd.
12.1.13. Pfizer Inc.
12.1.14. Sandoz International GmbH
12.1.15. Takeda Pharmaceutical Company Limited
12.2. Key Product Portfolio
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
FIGURE 1. MULTIPLE MYELOMA DRUG MARKET RESEARCH PROCESS
FIGURE 2. MULTIPLE MYELOMA DRUG MARKET SIZE, 2023 VS 2030
FIGURE 3. MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. MULTIPLE MYELOMA DRUG MARKET DYNAMICS
FIGURE 7. MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
FIGURE 8. MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
FIGURE 10. MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. MULTIPLE MYELOMA DRUG MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 20. MULTIPLE MYELOMA DRUG MARKET SHARE, BY KEY PLAYER, 2023

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us